GlobeNewswire by notified

Microbot Medical Announces New Webinar Series to Engage Stakeholders with Experts in the Healthcare Space

Share

The Access-Ability Live” by MBOT will build an online community of healthcare industry leaders who are interested in robotics to come together and share their opinion and experience

First Webinar on November 16th at 1:00pm ET will Focus on the Evolving Endovascular SpaceProcedures and How Emerging New Technologies such as the LIBERTY® Robotic System may be used by Physicians in the Future

HINGHAM, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be hosting a monthly educational webinar series, the Access-Ability Live by MBOT, to focus on key issues impacting the future of the endovascular space, including robotics and other medical devices that will improve patient outcomes, and the place that the LIBERTY® Robotic System is expected to play in it. Each month, the Company plans to partner with industry leaders, such as physicians, hospital administrators, entrepreneurs, technicians and financial experts for a live discussion and Q&A session to address top-of-mind healthcare related topics.

The initial webinar will be held on November 16, 2022, at 1:00 pm ET, and hosted by the Company’s Chief Medical Officer, Dr. Eyal Morag. Dr. Morag’s guest speaker will be Dr. Sebastian Flacke, a global leader in the endovascular space and Chief of Interventional Radiology and Director of non-invasive Cardiovascular Imaging at Lahey Hospital & Medical Center. Dr. Flacke is expected to address the current landscape for endovascular procedures, and how it has changed over the past and the emerging technologies being developed today that can potentially and significantly change how these procedures are going to be performed in the near future. Dr. Flacke will also share his recent hands-on experience with the LIBERTY Robotic System and the future impact that he believes it will have on his practice once the system is cleared for commercialization in the U.S.

“Over the last couple of months, we have noticed increased interest in our LIBERTY® Robotic System technology by multiple stakeholders, ranging from physicians, investors, strategic partners, and others, which coincides with our continued efforts towards the regulatory and commercialization phases,” commented Harel Gadot, Chairman, CEO and President. “To address this growing interest and ensure we are engaging with our key stakeholders, it’s critical they hear first-hand from industry experts about the growing unmet needs in the endovascular space, and how the LIBERTY Robotic System has the potential to resolve many of the challenges being experienced today. Our decision to launch the Access-Ability Live by MBOT webinar series is meant to establish an online community of industry leaders who are interested in robotics to come together and share their experience.”

To participate on the webinar, please register in advance at: https://us06web.zoom.us/webinar/register/WN_BslG0qO6QJem2Ew_gPSCuw. After registering, participants will receive a confirmation email containing information about joining the webinar.  

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY and the One & Done™ technologies, the outcome of its studies to evaluate LIBERTY, the One & Done™ technologies and other existing and future technologies, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

Michael Polyviou
EVC Group
mpolyviou@evcgroup.com
732-933-2754

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Robex: Strong Q2 Operational Results and Closing of the Transaction With Sycamore29.11.2022 01:47:16 CET | Press release

QUÉBEC CITY, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Robex Resources Inc. ("Robex", "the Group" or "the Company") (TSXV: RBX) is pleased to publish their financial results for the second quarter ended June 30, 2022. All amounts are in Canadian dollars (CAD). Quarterly Corporate Summary Operations: The number of ounces produced was 11,124 ounces, down by 1.7% compared to the same quarter in the previous year, specifically due to a much heavier rainy season in September that the start-up of the trommel as well as a higher feeding grade (0.82 g/t compared to 0.79 g/t for the same period in 2021) have not allowed to compensate. As a matter of fact, the unprecedented rainfall caused hopper procurement issues, loader cycle timing and availability issues, as well as clogging of the primary grizzly. At the beginning of October, the situation was back to normal. Exploration: During the third quarter of 2022, Robex continued significant exploration work completed by remote sensing on all its licences

Brookfield to Present at the Goldman Sachs 2022 US Financial Services Conference28.11.2022 22:01:00 CET | Press release

BROOKFIELD, NEWS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM, TSX: BAM.A) today announced that Bruce Flatt, Chief Executive Officer, is scheduled to present at the Goldman Sachs US Financial Services Conference on Wednesday, December 7, 2022, at 1:40pm ET. A live webcast will be available on the Brookfield website at https://bam.brookfield.com/news-events/events. For those unable to join the live webcast, a recording will be available on Brookfield’s website shortly after the event. About Brookfield Brookfield (NYSE: BAM, TSX: BAM.A) is a leading global alternative asset manager with over $750 billion of assets under management across real estate, infrastructure, renewable power and transition, private equity and credit. Brookfield owns and operates long-life assets and businesses, many of which form the backbone of the global economy. Utilizing its global reach, access to large-scale capital and operational expertise, Brookfield offers a range of alt

Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US28.11.2022 22:00:00 CET | Press release

New patent granted in the United States by the USPTO covers the use of lanifibranor for the potential treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage This patent strengthens and expands the intellectual property protection of lanifibranor in the United States particularly for use for patients with cirrhotic NASH Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced that the United States Patent and Trademark Office (“USPTO”) granted a patent (U.S. Patent No. 11,504,380) that protects the use of lanifibranor for the treatment of cirrhotic patients at risk of progressing from compensated stage to decompensa

EYES ON IRAN ART ACTIVATION FACES THE U.N. IN NEW YORK28.11.2022 21:04:15 CET | Press release

AN EVENT MARKED THE OPENING FEATURING HILLARY RODHAM CLINTON, GISSOU NIA,SHEIDA SOLEIMANI, SHIRIN NESHAT with SPECIAL PERFORMANCE BY JON BATISTE NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Iranian artists Sheida Soleimani, Aphrodite Désirée Navab, Z, Icy and Sot, Shirin Neshat, Mahvash Mostala, Sepideh Mehraban, and Shirin Towfiq, alongside artists Hank Willis Thomas and JR, activate New York’s FDR Four Freedoms State Park with a provocative multi-day and multi-media art installation facing the United Nations entitled Eyes on Iran, November 28, 2022 - January 1, 2023. Timed for the U.N. initiative, 16 Days of Activism Against Gender-Based Violence, the installations are focused on the power of collective sight, with eyes facing the U.N., signifying the world’s eyes on Iran. 'Eyes in the Sky' flying billboards featuring artworks by Thomas and Mostala will fly on December 3 in New York City and on November 28 and 30 in Miami. An interactive installation by artist JR will take place on